GlassScriptPhysician profile
Dhruvan Nimish Patel
NPI 1083055578
$11,768.27
in general payments reported to CMS, 2019-2025
40 companies · $4,534 in 2025
The $4,534 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $189 · 2021: $718 · 2022: $1,317 · 2023: $1,558 · 2024: $2,727 · 2025: $4,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,580 · Travel and Lodging: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,579.74 |
| Travel and Lodging | $1,239.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,753.75 | 2019-2025 | |
| Boston Scientific Corporation | $1,637.98 | 2019-2025 | Apollo Esg Nxt System, General - Therapies |
| Madrigal Pharmaceuticals | $1,511.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $1,034.94 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,033.84 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Scientific Affairs, LLC | $435.67 | 2024-2025 | Tremfya |
| Celgene Corporation | $335.81 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $313.99 | 2021-2025 | Eohilia, Gattex, Entyvio |
| Ardelyx, INC. | $311.45 | 2023-2025 | Ibsrela |
| Apollo Endosurgery US INC | $285.12 | 2021 | |
| Gilead Sciences, INC. | $208.10 | 2021-2025 | |
| Exact Sciences Corporation | $204.17 | 2023-2025 | Cologuard Collection Kit |
| Qol Medical, LLC | $184.88 | 2024-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $129.43 | 2021-2024 | Suflave |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruvan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.